Development and use of FRAX in osteoporosis
- PMID: 20464374
- DOI: 10.1007/s00198-010-1253-y
Development and use of FRAX in osteoporosis
Abstract
This paper reviews briefly the development and clinical use of FRAX in the development of assessment guidelines for osteoporosis.Fractures are the clinical consequence of osteoporosis and are a major cause of morbidity and mortality worldwide. Several treatments are available that have been shown to decrease the risk of fracture, but problems arise in identifying individuals at high fracture risk so that treatments can be effectively targeted. Case finding can be enhanced by the consideration of clinical risk factors that provide information on fracture risk over and above that provided by bone mineral density measurements. The FRAX tool integrates information on fracture risk from clinical risk factors with or without the use of BMD and can be used to improve the targeting of individuals at high fracture risk.
Similar articles
-
The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model.Osteoporos Int. 2017 Jan;28(1):127-137. doi: 10.1007/s00198-016-3766-5. Epub 2016 Sep 20. Osteoporos Int. 2017. PMID: 27650643
-
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28. Osteoporos Int. 2008. PMID: 18751937
-
Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.Osteoporos Int. 2010 Apr;21(4):647-53. doi: 10.1007/s00198-009-0984-0. Epub 2009 Jun 17. Osteoporos Int. 2010. PMID: 19533207
-
Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice.J Clin Densitom. 2017 Jul-Sep;20(3):334-345. doi: 10.1016/j.jocd.2017.06.019. Epub 2017 Jul 19. J Clin Densitom. 2017. PMID: 28734710 Review.
-
[FRAX--model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines].Lakartidningen. 2011 Feb 16-22;108(7):336-9. Lakartidningen. 2011. PMID: 21539116 Review. Swedish. No abstract available.
Cited by
-
Impact of patient education by nurse case managers on decision making for out-of-pocket anti-osteoporotic pharmaceutical therapy: a single-center retrospective study.BMC Nurs. 2024 Nov 6;23(1):808. doi: 10.1186/s12912-024-02467-x. BMC Nurs. 2024. PMID: 39506740 Free PMC article.
-
Autoantibodies Serum Level and 10-Year Risk of Fractures Evaluated by FRAX® Tool in Rheumatoid Arthritis Patients.Open Access Rheumatol. 2024 Jul 12;16:137-145. doi: 10.2147/OARRR.S466625. eCollection 2024. Open Access Rheumatol. 2024. PMID: 39045423 Free PMC article.
-
Enhancing osteoporosis management through risk assessment tools.Osteoporos Sarcopenia. 2024 Jun;10(2):45-46. doi: 10.1016/j.afos.2024.05.003. Epub 2024 May 31. Osteoporos Sarcopenia. 2024. PMID: 39035226 Free PMC article. No abstract available.
-
Exploring practice and perspectives on shared decision-making about osteoporosis medicines in Fracture Liaison Services: the iFraP development qualitative study.Arch Osteoporos. 2024 Jun 19;19(1):50. doi: 10.1007/s11657-024-01410-6. Arch Osteoporos. 2024. PMID: 38898212 Free PMC article.
-
Best Bisphosphonate Threshold for 10-Year Vertebral and Non-vertebral Fracture Mitigation.Cureus. 2024 May 7;16(5):e59830. doi: 10.7759/cureus.59830. eCollection 2024 May. Cureus. 2024. PMID: 38846189 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
